Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Adaptimmune Therapeutics plc (ADAP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.7300+0.0700 (+4.22%)
At close: 04:00PM EDT
1.7000 -0.03 (-1.73%)
After hours: 06:55PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close1.6600
Open1.6500
Bid1.7000 x 1100
Ask1.8300 x 900
Day's Range1.6500 - 1.8000
52 Week Range1.2600 - 6.8600
Volume388,853
Avg. Volume578,076
Market Cap280.293M
Beta (5Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)-1.0920
Earnings DateMay 09, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ADAP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Adaptimmune Therapeutics plc
    Analyst Report: BioNTech SEBioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.
    Rating
    Fair Value
    Economic Moat
    8 days agoMorningstar
View more
Advertisement
Advertisement